Complications and 5-year survival after radical resections which include urological organs for locally advanced and recurrent pelvic malignancies: analysis of 646 consecutive cases.
Adult
Aged
Aged, 80 and over
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ surgery
Pelvic Exenteration
/ adverse effects
Pelvic Neoplasms
/ surgery
Pelvis
Postoperative Complications
/ epidemiology
Rectal Neoplasms
/ surgery
Retrospective Studies
Treatment Outcome
Urinary Diversion
Young Adult
Local recurrence
Morbidity
Neoplasm recurrence
Pelvic exenteration
Pelvic neoplasms
Postoperative complications
Survival
Urinary diversion
Urinary tract
Journal
Techniques in coloproctology
ISSN: 1128-045X
Titre abrégé: Tech Coloproctol
Pays: Italy
ID NLM: 9613614
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
17
04
2019
accepted:
19
12
2019
pubmed:
8
1
2020
medline:
13
3
2021
entrez:
8
1
2020
Statut:
ppublish
Résumé
Extensive multi-visceral resection, including components of the urinary tract, is often required to achieve clear resection margins, which is now well established as a key predictor of long-term survival for locally advanced pelvic tumours. The aims of this study were to analyse major morbidity and factors predicting complications and long-term outcomes following a urological procedure within extended radical resections. Data were collected from prospective databases at two high-volume institutions specialising in extended radical resections for locally advanced and recurrent pelvic malignancies between 1990 and 2015. The primary endpoints were general major complications (Clavien-Dindo ≥ 3) and factors influencing complications and overall survival after urological resection. A total of 646 consecutive patients requiring an extended radical resection for locally advanced or recurrent pelvic malignancies were identified. The median age was 63 years (range 19-89 years) and the majority were female (371; 57.4%). A urological resection was performed as part of the resection in 226 patients (35.0%). The overall 30-day major complication rate was significantly higher in the urological intervention group (23%; n = 52) compared to the non-urological group (12.9%; n = 54 patients; p = 0.001). Intestinal anastomotic leak (p = 0.001) and intra-abdominal collections (p = 0.001) were more common in the urological cohort. Ileal conduit formation was an independent predictor of major morbidity (OR 1.95; 95% CI 1.24-3.07; p = 0.004). Independent prognostic markers for poor 5-year survival following urological procedures were recurrent tumour, cardiovascular disease, previous thromboembolic event and postoperative pulmonary embolism. Extended radical resections which include a urological resection are associated with significantly more major morbidity than those without urological resection. Ileal conduit formation is independently associated with the development of major morbidity. Five-year overall survival is no different for patients who had or did not have urological resection as part of extended radical surgery for locally advanced or recurrent pelvic malignancy.
Sections du résumé
BACKGROUND
Extensive multi-visceral resection, including components of the urinary tract, is often required to achieve clear resection margins, which is now well established as a key predictor of long-term survival for locally advanced pelvic tumours. The aims of this study were to analyse major morbidity and factors predicting complications and long-term outcomes following a urological procedure within extended radical resections.
METHODS
Data were collected from prospective databases at two high-volume institutions specialising in extended radical resections for locally advanced and recurrent pelvic malignancies between 1990 and 2015. The primary endpoints were general major complications (Clavien-Dindo ≥ 3) and factors influencing complications and overall survival after urological resection.
RESULTS
A total of 646 consecutive patients requiring an extended radical resection for locally advanced or recurrent pelvic malignancies were identified. The median age was 63 years (range 19-89 years) and the majority were female (371; 57.4%). A urological resection was performed as part of the resection in 226 patients (35.0%). The overall 30-day major complication rate was significantly higher in the urological intervention group (23%; n = 52) compared to the non-urological group (12.9%; n = 54 patients; p = 0.001). Intestinal anastomotic leak (p = 0.001) and intra-abdominal collections (p = 0.001) were more common in the urological cohort. Ileal conduit formation was an independent predictor of major morbidity (OR 1.95; 95% CI 1.24-3.07; p = 0.004). Independent prognostic markers for poor 5-year survival following urological procedures were recurrent tumour, cardiovascular disease, previous thromboembolic event and postoperative pulmonary embolism.
CONCLUSIONS
Extended radical resections which include a urological resection are associated with significantly more major morbidity than those without urological resection. Ileal conduit formation is independently associated with the development of major morbidity. Five-year overall survival is no different for patients who had or did not have urological resection as part of extended radical surgery for locally advanced or recurrent pelvic malignancy.
Identifiants
pubmed: 31907722
doi: 10.1007/s10151-019-02141-4
pii: 10.1007/s10151-019-02141-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
181-190Références
Can Urol Assoc J. 2015 May-Jun;9(5-6):E284-90
pubmed: 26029296
Am J Prev Med. 2014 Mar;46(3 Suppl 1):S7-15
pubmed: 24512933
Cancer Med. 2017 Jul;6(7):1573-1580
pubmed: 28639738
Br J Surg. 2019 Nov;106(12):1685-1696
pubmed: 31339561
Br J Surg. 2015 Jan;102(1):125-31
pubmed: 25451182
Eur J Surg Oncol. 2014 Jun;40(6):775-81
pubmed: 24144833
Eur J Surg Oncol. 2018 Oct;44(10):1513-1517
pubmed: 30017328
Ann Surg Oncol. 1999 Dec;6(8):732-8
pubmed: 10622500
ANZ J Surg. 2015 Jun;85(6):403-7
pubmed: 25823601
Colorectal Dis. 2012 Dec;14(12):1457-66
pubmed: 22356246
Am J Respir Crit Care Med. 2010 Mar 1;181(5):501-6
pubmed: 19965808
Gynecol Oncol. 2006 May;101(2):261-8
pubmed: 16426668
Gynecol Oncol. 2019 Jan;152(1):151-156
pubmed: 30414740
Eur J Surg Oncol. 2017 Oct;43(10):1869-1875
pubmed: 28732671
ANZ J Surg. 2018 Sep;88(9):896-900
pubmed: 29895098
Dis Colon Rectum. 2008 Mar;51(3):284-91
pubmed: 18204879
Cancer. 1948 Jul;1(2):177-83
pubmed: 18875031
Asian J Surg. 2011 Jul;34(3):115-20
pubmed: 22208686
Crit Rev Oncol Hematol. 2010 Dec;76(3):196-207
pubmed: 20036574
Ann Surg. 2019 Feb;269(2):315-321
pubmed: 28938268
ANZ J Surg. 2016 Jan-Feb;86(1-2):54-8
pubmed: 25113257
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Crit Rev Oncol Hematol. 2005 Sep;55(3):231-40
pubmed: 15979890
Ann Surg Oncol. 2009 Oct;16(10):2759-64
pubmed: 19680728
Ann Surg. 2014 Feb;259(2):315-22
pubmed: 23478530
J Surg Oncol. 2017 Mar;115(3):307-311
pubmed: 27859276
Br J Surg. 2013 Jul;100(8):1009-14
pubmed: 23754654
N Engl J Med. 2014 Jul 24;371(4):389-90
pubmed: 25054732
Urology. 2009 Nov;74(5):1138-43
pubmed: 19773042
Eur J Clin Invest. 2008 Oct;38 Suppl 2:45-9
pubmed: 18826481
Ann Surg. 2016 Aug;264(2):323-9
pubmed: 26692078
Arch Surg. 1994 Apr;129(4):390-5; discussion 395-6
pubmed: 8154965
Ann Surg Oncol. 2006 May;13(5):612-23
pubmed: 16538402
Eur J Surg Oncol. 2012 Apr;38(4):361-6
pubmed: 22265840
Gynecol Oncol. 2004 Feb;92(2):680-3
pubmed: 14766266
Surgery. 2010 Mar;147(3):339-51
pubmed: 20004450
JAMA Surg. 2017 Aug 1;152(8):784-791
pubmed: 28467526